EVR Research LP Invests $5.92 Million in Ingevity Corporation $NGVT

EVR Research LP bought a new position in Ingevity Corporation (NYSE:NGVT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $5,918,000. Ingevity makes up about 3.2% of EVR Research LP’s portfolio, making the stock its 13th biggest position.

Several other hedge funds also recently made changes to their positions in NGVT. Principal Financial Group Inc. grew its position in shares of Ingevity by 269.9% in the 4th quarter. Principal Financial Group Inc. now owns 652,237 shares of the company’s stock worth $38,599,000 after acquiring an additional 475,907 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock worth $23,769,000 after acquiring an additional 454,579 shares in the last quarter. Simcoe Capital Management LLC lifted its holdings in shares of Ingevity by 188.8% in the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company’s stock worth $26,928,000 after purchasing an additional 408,508 shares during the last quarter. Boston Partners lifted its holdings in shares of Ingevity by 141.6% in the 4th quarter. Boston Partners now owns 620,360 shares of the company’s stock worth $36,719,000 after purchasing an additional 363,584 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Ingevity by 137.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 424,038 shares of the company’s stock worth $25,095,000 after purchasing an additional 245,620 shares during the last quarter. Institutional investors and hedge funds own 91.59% of the company’s stock.

Ingevity Stock Up 0.1%

Shares of Ingevity stock opened at $71.82 on Thursday. The business’s fifty day moving average price is $71.45 and its two-hundred day moving average price is $67.61. The company has a debt-to-equity ratio of 27.83, a current ratio of 1.42 and a quick ratio of 0.92. The company has a market capitalization of $2.50 billion, a P/E ratio of -20.23 and a beta of 1.18. Ingevity Corporation has a 1-year low of $39.74 and a 1-year high of $79.29.

Ingevity (NYSE:NGVT) last announced its earnings results on Wednesday, May 6th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.31. The firm had revenue of $258.00 million for the quarter, compared to the consensus estimate of $254.73 million. Ingevity had a positive return on equity of 207.82% and a negative net margin of 10.55%.The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 EPS. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. As a group, research analysts forecast that Ingevity Corporation will post 5.05 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NGVT. BMO Capital Markets reissued an “outperform” rating and issued a $83.00 price target on shares of Ingevity in a report on Monday, March 2nd. Wells Fargo & Company raised their price target on Ingevity from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Wall Street Zen downgraded Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 13th. Jefferies Financial Group reissued a “buy” rating and issued a $82.00 price target on shares of Ingevity in a report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $80.00.

Insiders Place Their Bets

In other Ingevity news, SVP Terrance M. Dyer sold 496 shares of Ingevity stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the sale, the senior vice president owned 7,202 shares of the company’s stock, valued at $493,264.98. The trade was a 6.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.88% of the stock is owned by insiders.

Ingevity Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.